Literature DB >> 22104271

Expression of hypoxia-inducible factor 1α predicts clinical outcome after preoperative hyperthermo-chemoradiotherapy for locally advanced rectal cancer.

Mariko Shioya1, Takeo Takahashi, Hitoshi Ishikawa, Hideyuki Sakurai, Takeshi Ebara, Yoshiyuki Suzuki, Jun-ichi Saitoh, Tatsuya Ohno, Takayuki Asao, Hiroyuki Kuwano, Takashi Nakano.   

Abstract

Hypoxia-inducible factor 1α (HIF-1α) is an intrinsic marker of tumor hypoxia. It has been considered that hypoxic conditions reduce radiosensitivity, but the role of HIF-1α in patients treated with preoperative therapy for rectal cancer is still unclear. The aim of this study was to evaluate the predictive value of tumor response to preoperative hyperthermo-chemoradiotherapy (HCRT) and the prognostic significance of HIF-1α expression in patients with locally advanced rectal cancer. Between 2003 and 2006, 50 patients with histologically proven rectal adenocarcinoma who underwent HCRT followed by surgery were investigated. HIF-1α expression was immunohistochemically evaluated using pre-treatment biopsies. The total radiation dose was 40-50 Gy and chemotherapy consisted of 5-FU and LV administered by continuous infusion on Day 1-5, Day 15-19, and Day 29-33 during radiotherapy. Hyperthermia treatment was performed for once a week for 2-5 sessions. The surgical operation was performed 8 weeks after HCRT and each resected specimen was graded by histological criteria of the Japanese Classification of Colorectal Carcinoma. The effects of HIF-1α on clinical outcomes were analyzed by univariate and multivariate analysis. Positive HIF-1α expression was recognized in 42.0% of samples (21/50). Resected specimens that showed pathological grades 1, 2, and 3 numbered 17, 24, and 9 cases, respectively. There were no significant differences between the HIF-1α-positive group and HIF-1α-negative group for pathological grading and pCR. Overall survival (OS) rate at 3 years in the HIF-1α-negative group was 85.2%, which was significantly better than the 60.6% in the HIF-1α-positive group. Recurrence-free survival (RFS) rate at 3 years in the HIF-1α-negative group was 82.8%, being significantly better than 47.6% in the HIF-1α-positive group. In addition, elevated HIF-1α expression was significantly correlated with recurrence-free survival and metastasis-free survival rate in multivariate analysis. HIF-1α expression might be predictive of recurrence-free survival and metastasis-free survival rate for rectal cancer patients treated with HCRT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22104271     DOI: 10.1269/jrr.11117

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  10 in total

1.  Overexpression of nuclear β-catenin in rectal adenocarcinoma is associated with radioresistance.

Authors:  Lin Wang; Xiao-Mei Zhang; Zhen Li; Xi-Jun Liu; Jie Chai; Guang-Yong Zhang; Yu-Feng Cheng
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

2.  Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Sang-Won Kim; Ji Woon Yea; Jae Hwang Kim; Mi Jin Gu; Min Kyu Kang
Journal:  Int J Clin Oncol       Date:  2017-11-13       Impact factor: 3.402

3.  hPEBP4 as a predictive marker for the pathological response of rectal cancer to preoperative radiotherapy.

Authors:  Jianming Qiu; Guangen Yang; Zhong Shen; Ya Xie; Lewei Wang
Journal:  Int J Colorectal Dis       Date:  2012-07-17       Impact factor: 2.571

4.  Prognostic value of HIF-1α in digestive system malignancies: evidence from a systematic review and meta-analysis.

Authors:  Mohammad-Hassan Arjmand; Ali Moradi; Hamid-Reza Rahimi; Ali Es-Haghi; Abolfazl Akbari; Mohammad Reza Hadipanah; Jalil Afshar; Hassan Mehrad-Majd
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

5.  HLA class I expression and its alteration by preoperative hyperthermo-chemoradiotherapy in patients with rectal cancer.

Authors:  Hiro Sato; Yoshiyuki Suzuki; Munenori Ide; Toshihide Katoh; Shin-Ei Noda; Ken Ando; Takahiro Oike; Yuya Yoshimoto; Noriyuki Okonogi; Kousaku Mimura; Takayuki Asao; Hiroyuki Kuwano; Takashi Nakano
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

6.  The prognostic value of hypoxia-inducible factor-1α in advanced cancer survivors: a meta-analysis with trial sequential analysis.

Authors:  Susu Han; Tao Huang; Fenggang Hou; Liting Yao; Xiyu Wang; Xing Wu
Journal:  Ther Adv Med Oncol       Date:  2019-09-24       Impact factor: 8.168

Review 7.  Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancers: HIF-1α and Beyond.

Authors:  Shing Yau Tam; Vincent W C Wu; Helen K W Law
Journal:  Front Oncol       Date:  2020-04-08       Impact factor: 6.244

Review 8.  The measurement and modification of hypoxia in colorectal cancer: overlooked but not forgotten.

Authors:  Teddy Fletcher; Alex J Thompson; Hutan Ashrafian; Ara Darzi
Journal:  Gastroenterol Rep (Oxf)       Date:  2022-08-25

9.  Prognostic value and clinicopathological differences of HIFs in colorectal cancer: evidence from meta-analysis.

Authors:  Zhigang Chen; Xin He; Wenjie Xia; Qi Huang; Zhigang Zhang; Jun Ye; Chao Ni; Pin Wu; Dang Wu; Jinghong Xu; Fuming Qiu; Jian Huang
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

10.  A Panel of Tumor Biomarkers to Predict Complete Pathological Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer.

Authors:  Chiara Dalle Fratte; Silvia Mezzalira; Jerry Polesel; Elena De Mattia; Antonio Palumbo; Angela Buonadonna; Elisa Palazzari; Antonino De Paoli; Claudio Belluco; Vincenzo Canzonieri; Giuseppe Toffoli; Erika Cecchin
Journal:  Oncol Res       Date:  2021-06-09       Impact factor: 5.574

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.